Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission

BACKGROUND: The presence of minimal residual disease (MRD) is an independent risk factor for poor prognosis in patients with acute lymphoblastic leukemia (ALL). Moreover, the role of chimeric antigen receptor T-cell (CAR-T) therapy in patients with MRD is currently unclear. METHODS: We conducted a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Guan-hua, Cheng, Yi-fei, Zuo, Ying-xi, Chang, Ying-jun, Suo, Pan, Wu, Jun, Jia, Yue-ping, Lu, Ai-dong, Li, Ying-chun, Wang, Yu, Jiao, Shun-chang, Zhang, Long-ji, Zhao, Xiang-yu, Yan, Chen-hua, Xu, Lan-ping, Zhang, Xiao-hui, Liu, Kai-yan, Zhang, Le-ping, Huang, Xiao-jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777073/
https://www.ncbi.nlm.nih.gov/pubmed/35069522
http://dx.doi.org/10.3389/fimmu.2021.731435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777073/
https://www.ncbi.nlm.nih.gov/pubmed/35069522
http://dx.doi.org/10.3389/fimmu.2021.731435

Ejemplares similares